MedTrace Logo

Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With Metformin in Healthy Male Adults (Phase 1 Study)

NCT04064073 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2020-01-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate drug-drug interaction of DWP16001 in combination with metformin IR 1000mg in Healthy male subjects.

Conditions

  • Healthy

Interventions

DRUG

DWP16001

Tablets, Oral, once daily single dose

DRUG

Metformin IR

Metformin IR 1000mg, Tablets, Oral, BID for 7 days

DRUG

DWP16001+Metformin IR

Tablets, Oral, once daily single dose DWP16001 Metformin IR 1000mg

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-14
Primary Completion
2019-11-20
Completion
2019-11-20

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04064073 on ClinicalTrials.gov